重组人白细胞介素-11减轻初发急性白血病诱导化疗后血小板减少的作用观察

The Efficacy of Recombinant Human Interleukin-11 in Chemotherapy Induced Thrombocytopenia of Initial Acute Leukemia

目的观察重组人白细胞介素-11(rhIL-11)治疗初发急性白血病患者诱导化疗后血小板减少的疗效和安全性,并探讨其作用机制.方法初发急性白血病患者60例,诱导化疗结束后用rhIL-1150μg(/kg.d)皮下注射,连用4～14d;对照组59例,为同期住院治疗的初发急性白血病患者,化疗后不给予rhIL-11治疗.对比观察两组的疗效.结果治疗组较对照组血小板恢复时间短,输注单采血小板数量少,两组比较差异均有统计学意义(P<0.05).患者常见的不良反应如水肿、乏力、恶心和肌肉关节酸痛等,治疗组程度较轻,而且在停药后自行消失.结论rhIL-11治疗初发急性白血病患者诱导化疗后血小板减少有效、安全,可加速血小板数量的恢复,减少患者对血小板输注的需求.

Objective To observe the efficacy,safety and possible mechanism of recombinant human interleukin-11 （ rhIL-11）in chemotherapy induced thrombocytopenia of initial acute leukemia.Methods 60 initial acute leukemia patients were treated with rhIL-11 after the completion of chemotherapy at 50 μg/（kg·d）, injection for 4 ～14 days.59 acute leukemia patients during the same time entered into the control group. Results The platelet counts of the treatment group after using rhIL-11 was statistically different with the control group （P 〈0. 05）.Meanwhile, the amount of platelet transfusion in treatment group was less than those of control group （P 〈0.05）.Major adverse events associated with rhIL-11 were fatigue, edema, nausea, callosity and so on.They were mild, reversible with drug discontinuation and easily managed.Conclusion RhIL-11 can safely accelerate the recovery of chemotherapy induced thrombocytopenia in initial acute leukemia and decrease the requirement for platelet transfusion.